Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
David Jin is Director at Mustang Bio. OQRO lists 1 transaction filed with the SEC under this name, the latest on Dec 30, 2025, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
David Jin bought shares on the open market in 2022, 2023, 2024 and 2025 across 2 companies.
David Jin reported 4 open-market purchases and 0 sales since 2022; purchases in 4 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $2381×1 trade | — |
| 2024 | $3.8K1×1 trade | — |
| 2023 | $30K1×1 trade | — |
| 2022 | $2.8K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
1 buy, median −21.2 pts vs S&P 500, beat it 0 of 1 time.
Average −21.2 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Dec 30, 2025 to Dec 30, 2025, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index. $1,000 placed after each of the 1 purchases disclosed since 2025-11-16 would be worth $430 today ($1K put in); the same in the S&P 500 (SPY): $1.1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Mustang BioMBIO
Dec 30, 2025Bought~$238
DetailsOfficial recordAs of the latest filing on , David Jin reported holding 1,652,761 shares of Fortress Biotech (FBIO), worth about $2.83M at the last close of $2 (Nov 16, 2026). Holdings are also on file at Mustang Bio (MBIO); together they are worth about $2.83M. In the last 12 months, David Jin bought $238 in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Fortress Biotech FBIO | 1,652,761 | 1.65M direct | $2 | $2.83M | Oct 1, 2026 |
| Mustang Bio MBIO | 286 | 286 direct | $0 | $113 | Dec 30, 2025 |
Is this David Jin’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Oct 1, 2026, David Jin reported holding 1,652,761 shares of Fortress Biotech (FBIO). At the last close of $2 on Nov 16, 2026, that is about $2.83M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, David Jin reported 1 open-market purchase worth $238, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
David Jin bought shares on the open market in 2022, 2023, 2024 and 2025 across 2 companies.
In SEC filings since 2022: the latest open-market purchase is from 2025; no open-market sale is on record.
2 companies: Mustang Bio (MBIO, 2025), Fortress Biotech (FBIO, 2022–2024).
David Jin reported 3 open-market purchases and 0 sales here, 2022 to 2024.
David Jin reported 1 open-market purchase and 0 sales here, 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.